Joint Study By Rosetta Genomics And NYU Langone Medical Center Identifies Single MicroRNA Biomarker For Prognosis Of Mesothelioma Patients

| Feb 19, 2010

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announced today that the results of a joint study with the NYU Langone Medical Center were published online on February 16th, 2010, and are set to be published in the March 1st issue of the American Association for Cancer Research’s journal, Cancer Research…

Related Posts:

  1. Cognition Research Aims To Reduce Medical Errors
  2. Link Between Impaired Judgment Of Harmful Intent And Damage To Prefrontal Cortex
  3. $3.58 Million Gift Will Forward Scientific Advances For Mesothelioma Research, One Of The Most Difficult To Treat Cancers
  4. AMGA Lauds Senator Stabenow For Her Efforts To Ensure EMR Incentives For Medical Groups
  5. AMA Gives Qualified Support To Health Bill, Texas Docs Disagree

Filed Under: Toxic Injury